The Latest Updates from ReSPECT Clinical Trials
NCCN Curtain Raiser
Visit our poster at the National Comprehensive Cancer Network® (NCCN®) conference today and say hello to our clinical team! The poster will be available on our website after the conference
Plus Approach
Plus Therapeutics' novel approach to treating Glioblastoma overcomes the limitations of all three currently employed treatment modalities. Leveraging established, targeted delivery techniques, we seek to inject high doses of radiation directly into or near a cancer...
Welcome Frank
We are pleased to introduce Frank Gonzalez Rodriguez as Senior Clinical Trial Associate at Plus Therapeutics! He is looking forward to being on the sponsor side of our clinical trials and part of our clinical operations team....
Cancer Control Month
April is dedicated to raising awareness for cancer prevention and treatment throughout the US. 🎗️ At Plus Therapeutics, we seek to help patients and clinicians find safe, lasting solutions for treating rare and difficult-to-treat cancers....
Happy Doctor’s Day
We want to thank all of the #doctors and Principal Investigators we get to work with to help us run our #clinicaltrials and provide #treatment options for #patients! They all are great supporters of our mission to solve the toughest challenges in #oncology 🩺...
CSF-01 Implementation
In case you missed it, we announced the validation & clinical implementation of our CSF-01 Leptomeningeal Cancer Cell Diagnostic. The CSF-01 cancer cell enumeration test is an exploratory endpoint in the ReSPECT-LM Phase 1 trial that has shown promise in the...
NCCN Curtain Raiser
❗Mark Your Calendars❗ Plus Therapeutics will be presenting a poster at the National Comprehensive Cancer Network Annual Conference Press release: https://bit.ly/PSTV_PR #NCCN #BrainCancer #Glioblastoma #BreastCancer #LungCancer #ClinicalTrials
Susan G. Komen: LM
Thank you to @SusanGKomen for adding "Leptomeningeal Metastasis" to your Breast Cancer Glossary patient resource! 🎗️ "Leptomeningeal Metastasis: Cancer that spreads from the original tumor to the meninges (the thin layers of tissue that cover and protect the brain and...
CSF-01 Announcement
BREAKING NEWS: Plus Therapeutics Announces Validation & Clinical Implementation of CSF-01 Leptomeningeal Cancer Cell Diagnostic > Plus’ CSF-01 cancer cell enumeration test is a sensitive and specific diagnostic test for the presence of adenocarcinoma and...
IR Events
Want to hear the latest milestones from our team? We have replays of all our events and earnings calls on our website at IR.PlusTherapeutics.com/Events. Questions about any of the recorded events? Contact us at https://ir.plustherapeutics.com/resources/contact-ir...
Head for the Cure Austin
Join some of the Plus Therapeutics team at the @HeadfortheCure 5K in Austin, TX on March 24! They will be out supporting the local community, cancer research, and "Defeating Brain Cancer Step by Step." We hope to see you there 🏃🏃♂️🏃♀️ Event information:...
Corporate Presentation
AVAILABLE NOW: The new Plus Therapeutics corporate presentation, which reflects our current data, milestones, and pipeline, is on our website. View it directly here: https://bit.ly/3PiHClj Questions about anything or interested in learning more? Visit our website at...
LM Cohort 5 Completion
BREAKING NEWS! We have completed dosing in Cohort 5 of our ongoing ReSPECT-LM Phase 1 Trial of Rhenium (186Re) Obisbemeda in Leptomeningeal Metastases, with a total of 18 patients have been dosed in the trial to date. The trial is STILL ENROLLING and accepting new...
“Glioblastoma AKA GBM” Sponsorship
We are thrilled to announce our sponsorship with @glioblastomaresearch this upcoming season on their "Glioblastoma AKA GBM" podcast! 🧠 We appreciate their goal of raising awareness and funds for new global, cutting-edge research to find a cure for Glioblastoma and...
Miami Breast Conference
Some of our clinical team will be attending the #MiamiBreast Cancer Conference this week, as it relates to our Leptomeningeal Metastases clinical trial for Metastatic Breast Cancer patients. If you are interested in connecting with the team there, send us a DM. See...
Rare Disease Day 2024
Today on leap day, the rarest day of the year, we celebrate Rare Disease Day along with the NIH and other organizations. Plus Therapeutics is dedicated to developing innovative, targeted radiotherapeutics for adult & pediatric patients with rare &...
Head for the Cure Sponsorship
We are excited to announce our national partnership with @HeadfortheCure! 🎉 Their goals of building awareness, raising funds, and igniting hope for the brain tumor community strongly align with our mission. Look out for more information regarding our upcoming...
ABTA Collaboration
We love working with the @the_ABTA and are so excited about our upcoming collaborative projects with them. More to come‼️ ABTA Brain Tumor Resources: https://www.abta.org/about-brain-tumors/ ReSPECT-GBM Clinical Trial Patient Resource:...
UMMC Nuclear Medicine Conference
We will see you at the Nuclear Medicine Conference at the University of Mississippi Medical Center this weekend! Come grab some information on our ReSPECT-GBM and ReSPECT-LM clinical trials https://www.respect-trials.com/ #NuclearMedicine #ClinicalTrials #Oncology...
LM Patient Study Guide
⭐ We have a NEW Patient Guide for our Leptomeningeal Metastases trial available NOW on our website at ReSPECT-Trials.com! Please share this resource with caregivers and patients that may be interested in enrolling for our Phase 1 ReSPECT-LM clinical trial. #BrainMets...
Contents
- 1 The Latest Updates from ReSPECT Clinical Trials
- 1.1 NCCN Curtain Raiser
- 1.2 Plus Approach
- 1.3 Welcome Frank
- 1.4 Cancer Control Month
- 1.5 Happy Doctor’s Day
- 1.6 CSF-01 Implementation
- 1.7 NCCN Curtain Raiser
- 1.8 Susan G. Komen: LM
- 1.9 CSF-01 Announcement
- 1.10 IR Events
- 1.11 Head for the Cure Austin
- 1.12 Corporate Presentation
- 1.13 LM Cohort 5 Completion
- 1.14 “Glioblastoma AKA GBM” Sponsorship
- 1.15 Miami Breast Conference
- 1.16 Rare Disease Day 2024
- 1.17 Head for the Cure Sponsorship
- 1.18 ABTA Collaboration
- 1.19 UMMC Nuclear Medicine Conference
- 1.20 LM Patient Study Guide